These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1237 related items for PubMed ID: 22989472

  • 1. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H, Hartmann B, Holst JJ, Viby NE, Hansen LS, Rosenkilde MM, Hare KJ, Poulsen SS.
    Regul Pept; 2012 Nov 10; 179(1-3):91-100. PubMed ID: 22989472
    [Abstract] [Full Text] [Related]

  • 2. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF, Mannucci E, Ahrén B.
    Diabetes Obes Metab; 2012 Aug 10; 14(8):762-7. PubMed ID: 22471248
    [Abstract] [Full Text] [Related]

  • 3. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ.
    J Am Pharm Assoc (2003); 2009 Aug 10; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [Abstract] [Full Text] [Related]

  • 4. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B, Bonnard C, Renard E.
    Diabetes Metab; 2011 Dec 10; 37(6):477-88. PubMed ID: 21871831
    [Abstract] [Full Text] [Related]

  • 5. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Freeman JS.
    Cleve Clin J Med; 2009 Dec 10; 76 Suppl 5():S12-9. PubMed ID: 19952298
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS.
    Postgrad Med; 2011 Jan 10; 123(1):53-65. PubMed ID: 21293084
    [Abstract] [Full Text] [Related]

  • 9. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
    Madsbad S, Krarup T, Deacon CF, Holst JJ.
    Curr Opin Clin Nutr Metab Care; 2008 Jul 10; 11(4):491-9. PubMed ID: 18542012
    [Abstract] [Full Text] [Related]

  • 10. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L, Montanya E.
    Diabetes Obes Metab; 2012 Apr 10; 14 Suppl 2():20-32. PubMed ID: 22405266
    [Abstract] [Full Text] [Related]

  • 11. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ, Nauck MA.
    Lancet; 2006 Nov 11; 368(9548):1696-705. PubMed ID: 17098089
    [Abstract] [Full Text] [Related]

  • 12. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z.
    Diabetes Obes Metab; 2013 Aug 11; 15(8):737-49. PubMed ID: 23433305
    [Abstract] [Full Text] [Related]

  • 13. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ.
    Expert Opin Emerg Drugs; 2004 May 11; 9(1):155-66. PubMed ID: 15155141
    [Abstract] [Full Text] [Related]

  • 14. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
    Zambrowicz B, Ding ZM, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J, Smith M, Ruff D, Sands A, Powell D.
    Clin Ther; 2013 Mar 11; 35(3):273-285.e7. PubMed ID: 23433601
    [Abstract] [Full Text] [Related]

  • 15. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice.
    Thulesen J, Hartmann B, Hare KJ, Kissow H, Ørskov C, Holst JJ, Poulsen SS.
    Gut; 2004 Aug 11; 53(8):1145-50. PubMed ID: 15247183
    [Abstract] [Full Text] [Related]

  • 16. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
    Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A, Kaufman B, Rubinek T.
    Breast Cancer Res Treat; 2012 Apr 11; 132(2):449-61. PubMed ID: 21638053
    [Abstract] [Full Text] [Related]

  • 17. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
    Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ.
    Diabetes Obes Metab; 2011 May 11; 13(5):394-407. PubMed ID: 21208359
    [Abstract] [Full Text] [Related]

  • 18. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
    Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, Xu G, Pu Y, Zhu Z, Xu A, Lam KS, Chen ZY, Ng CF, Yao X, Huang Y.
    Hypertension; 2012 Sep 11; 60(3):833-41. PubMed ID: 22868389
    [Abstract] [Full Text] [Related]

  • 19. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE, Davies M, 1860-LIRA-DPP-4 Study Group.
    Lancet; 2010 Apr 24; 375(9724):1447-56. PubMed ID: 20417856
    [Abstract] [Full Text] [Related]

  • 20. On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice.
    Rosol TJ.
    Toxicol Pathol; 2013 Feb 24; 41(2):303-9. PubMed ID: 23471186
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.